Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study

作者：Xiaohong Fan, Xiahong Dai, Yun Ling, Lihua Wu, Lingling Tang, Chunxian Peng, Chaolin Huang, Hongyan Liu, Hongzhou Lu, Xinghua Shen, Wei Zhang, Furong Wang, Guangming Li, Ming Li, Yanming Huang, Hongying Zhang, Minghui Li, Fei Ren, Yuanyuan Li, Chenfan Liu, Zhiguo Zhou, Wei Sun, Yongxiang Yi, Daming Zhou, Hainv Gao, Qi Pan, Hongde Liu, Jiang Zhao, Zhen Ding, Yingmin Ma, Wei Li, Quanhong Wang, Xicheng Wang, Yichun Bai, Xiangao Jiang, Juan Ma, Bingying Xie, Kui Zhang, Lanjuan Li · 发表于：The Lancet Infectious Diseases · 年份：2023 · DOI：10.1016/s1473-3099(23)00577-7 · 被引用次数：48 · 研究领域：SARS-CoV-2 and COVID-19 Research、COVID-19 Clinical Research Studies、Long-Term Effects of COVID-19